Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.

Simon, Audrey; Peoch, Michel; Casassus, Philippe; Deconinck, Eric; Colombat, Philippe; Desablens, Bernard; Tournilhac, Olivier; Eghbali, Houchingue; Foussard, Charles; Jaubert, Jerome; Vilque, Jean Pierre; Rossi, Jean François; Lucas, Virginie; Delwail, Vincent; Thyss, Antoine; Maloisel, Frederic; Milpied, Noel; le Gouill, Steven; Lamy, Thierry; Gressin, Rémy

Simon, Audrey; Peoch, Michel; Casassus, Philippe; Deconinck, Eric; Colombat, Philippe; Desablens, Bernard; Tournilhac, Olivier; Eghbali, Houchingue; Foussard, Charles; Jaubert, Jerome; Vilque, Jean Pierre; Rossi, Jean François; Lucas, Virginie; Delwail, Vincent; Thyss, Antoine; Maloisel, Frederic; Milpied, Noel; le Gouill, Steven; Lamy, Thierry; Gressin, Rémy.

Affiliation

Simon A; Centre Hospitalo-Universitaire Grenoble, France.

Br J Haematol ; 151(2): 159-66, 2010 Oct.

Article in En | MEDLINE | ID: mdl-20738307

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, T-Cell, Peripheral Type of study: Clinical_trials / Diagnostic_studies / Prognostic_studies Language: En Journal: Br J Haematol Year: 2010 Document type: Article Affiliation country: Francia Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google